American Century Companies Inc. Buys 10,840 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)

American Century Companies Inc. lifted its position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) by 31.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,444 shares of the company’s stock after acquiring an additional 10,840 shares during the period. American Century Companies Inc. owned approximately 0.08% of Acumen Pharmaceuticals worth $110,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ABOS. Price T Rowe Associates Inc. MD acquired a new position in Acumen Pharmaceuticals in the first quarter valued at about $4,449,000. Parkman Healthcare Partners LLC grew its position in shares of Acumen Pharmaceuticals by 20.7% in the 4th quarter. Parkman Healthcare Partners LLC now owns 603,497 shares of the company’s stock valued at $2,317,000 after purchasing an additional 103,683 shares during the period. Bank of New York Mellon Corp bought a new stake in Acumen Pharmaceuticals during the 2nd quarter worth approximately $306,000. Susquehanna Fundamental Investments LLC acquired a new stake in Acumen Pharmaceuticals during the 1st quarter worth approximately $253,000. Finally, Rhumbline Advisers bought a new position in Acumen Pharmaceuticals in the second quarter valued at approximately $127,000. Institutional investors own 71.01% of the company’s stock.

Acumen Pharmaceuticals Stock Performance

Shares of ABOS stock opened at $2.37 on Friday. Acumen Pharmaceuticals, Inc. has a 12 month low of $1.81 and a 12 month high of $5.09. The company’s fifty day simple moving average is $2.65 and its 200-day simple moving average is $3.00. The firm has a market cap of $142.39 million, a PE ratio of -2.24 and a beta of 0.07. The company has a quick ratio of 17.37, a current ratio of 17.37 and a debt-to-equity ratio of 0.12.

Acumen Pharmaceuticals (NASDAQ:ABOS) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). During the same period in the prior year, the business posted ($0.28) EPS. Equities research analysts expect that Acumen Pharmaceuticals, Inc. will post -1.32 EPS for the current fiscal year.

Analyst Ratings Changes

ABOS has been the subject of several research reports. UBS Group lowered their price objective on shares of Acumen Pharmaceuticals from $14.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Acumen Pharmaceuticals in a report on Thursday. Finally, Citigroup upgraded Acumen Pharmaceuticals to a “strong-buy” rating in a report on Friday, July 26th.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.